Infection and Immunity, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.
Clin Infect Dis. 2021 Jan 23;72(1):99-107. doi: 10.1093/cid/ciz1238.
Data on influenza vaccine effectiveness (IVE) against mortality are limited, with no Australian data to guide vaccine uptake. We aimed to assess IVE against influenza-related mortality in Australian hospitalized patients, assess residual confounding in the association between influenza vaccination and mortality, and assess whether influenza vaccination reduces the severity of influenza illness.
Data were collected between 2010 and 2017 from a national Australian hospital-based sentinel surveillance system using a case-control design. Adults and children admitted to the 17 study hospitals with acute respiratory symptoms were tested for influenza using nucleic acid testing; all eligible test-positive cases, and a subset of test-negative controls, were included. Propensity score analysis and multivariable logistic regression were used to determine the adjusted odds ratio (aOR) of vaccination, with IVE = 1 - aOR × 100%. Residual confounding was assessed by examining mortality in controls.
Over 8 seasons, 14038 patients were admitted with laboratory-confirmed influenza. The primary analysis included 9298 cases and 6451 controls, with 194 cases and 136 controls dying during hospitalization. Vaccination was associated with a 31% (95% confidence interval [CI], 3%-51%; P = .033) reduction in influenza-related mortality, with similar estimates in the National Immunisation Program target group. Residual confounding was identified in patients ≥65 years old (aOR, 1.92 [95% CI, 1.06-3.46]; P = .031). There was no evidence that vaccination reduced the severity of influenza illness (aOR, 1.07 [95% CI, .76-1.50]; P = .713).
Influenza vaccination is associated with a moderate reduction in influenza-related mortality. This finding reinforces the utility of the Australian vaccination program in protecting those most at risk of influenza-related deaths.
关于流感疫苗效力(IVE)对死亡率的影响的数据有限,澳大利亚没有数据可以指导疫苗接种。我们旨在评估澳大利亚住院患者中流感相关死亡率的 IVE,评估流感疫苗接种和死亡率之间的关联中残余混杂因素,并评估流感疫苗接种是否降低流感疾病的严重程度。
使用病例对照设计,从 2010 年至 2017 年,从一个全国性的澳大利亚基于医院的哨点监测系统中收集数据。对因急性呼吸道症状入住 17 家研究医院的成年人和儿童进行流感核酸检测;所有符合条件的检测阳性病例,以及部分检测阴性对照,均被纳入研究。使用倾向评分分析和多变量逻辑回归来确定接种的调整比值比(aOR),IVE = 1 - aOR × 100%。通过检查对照组的死亡率来评估残余混杂因素。
在 8 个季节中,有 14038 名患者因实验室确诊的流感住院。主要分析纳入了 9298 例病例和 6451 例对照,其中 194 例病例和 136 例对照在住院期间死亡。接种疫苗与流感相关死亡率降低 31%(95%置信区间 [CI],3%-51%;P =.033)相关,在国家免疫计划目标人群中也有类似的估计。在≥65 岁的患者中发现了残余混杂因素(aOR,1.92 [95% CI,1.06-3.46];P =.031)。没有证据表明接种疫苗降低了流感疾病的严重程度(aOR,1.07 [95% CI,.76-1.50];P =.713)。
流感疫苗接种与流感相关死亡率的适度降低相关。这一发现加强了澳大利亚疫苗接种计划在保护那些最易受流感相关死亡影响的人群方面的作用。